Results 151 to 160 of about 6,097,409 (251)

The use of PET/CT in Radiotherapy Planning: Contribution of Deformable Registration

open access: yesFrontiers in Oncology, 2013
Ela eDelikgoz Soykut   +7 more
doaj   +1 more source

How bone mis-segmentation affects MRI-based sCT dosimetry in head and neck radiotherapy: A CT-referenced study. [PDF]

open access: yesJ Appl Clin Med Phys
Sayaque L   +7 more
europepmc   +1 more source

Living at genetic risk: The patient experience of Lynch syndrome

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Lynch syndrome is a germline cancer predisposition syndrome caused by a variant in one of four genes. Lynch syndrome places individuals at significantly higher risk for a range of cancers, especially colorectal and endometrial. Depending on which gene is affected, the risk of ovarian, gastric, small bowel, pancreatic, biliary urothelial, brain,
Nicola Reents   +2 more
wiley   +1 more source

Pretreatment EBV‐DNA/TLG‐Based Risk Stratification Is Associated With Survival Outcomes in Nonmetastatic Nasopharyngeal Carcinoma: An Exploratory Study

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Whether combining pretreatment plasma Epstein–Barr virus DNA (EBV‐DNA) with 18F‐FDG PET/CT‐derived total lesion glycolysis (TLG) improves prognostic stratification in nonmetastatic nasopharyngeal carcinoma (NPC) is unclear, particularly in nonendemic populations.
Mehmet Çağrı Duymaz   +7 more
wiley   +1 more source

Longitudinal Associations of Oxaliplatin Treatment With Chemotherapy‐Induced Peripheral Neuropathy in Colorectal cancer Survivors up to 2 Years Post‐Treatment

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Chemotherapy‐induced peripheral neuropathy (CIPN) is a potentially long‐term consequence of oxaliplatin‐based chemotherapy for colorectal cancer (CRC). Oxaliplatin dosing is based on body surface area (BSA), but lean body mass (LBM) may influence susceptibility to long‐term CIPN.
Nadira R. Querido   +10 more
wiley   +1 more source

Real‐World Experience With Multimodal Treatment of Resectable Stage II–III Non‐Small Cell Lung Cancer: A Single Institutional Analysis

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Neoadjuvant therapy has recently become an integral component of multimodal treatment for resectable lung cancer. However, real‐world data on perioperative morbidity and treatment adherence remain limited. This study aimed to assess the feasibility and safety of different neoadjuvant treatment approaches applied within daily clinical routine ...
Raffaella Griffo   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy